BR112018007118A2 - method for treating a dopamine deficiency disorder, method for improving active motor time without dyskinesia in a patient with parkinson's disease, method for reducing dyskinesia in an individual with a dopamine deficiency disorder, method for reducing inactive motor time in an individual with a dopamine deficiency disorder, method for reducing striatal dopamine level fluctuations in an individual with a dopamine deficiency disorder, method for reducing dyskinesia in an individual with a dopamine deficiency disorder after long-term treatment, pharmaceutical composition and packaging - Google Patents
method for treating a dopamine deficiency disorder, method for improving active motor time without dyskinesia in a patient with parkinson's disease, method for reducing dyskinesia in an individual with a dopamine deficiency disorder, method for reducing inactive motor time in an individual with a dopamine deficiency disorder, method for reducing striatal dopamine level fluctuations in an individual with a dopamine deficiency disorder, method for reducing dyskinesia in an individual with a dopamine deficiency disorder after long-term treatment, pharmaceutical composition and packagingInfo
- Publication number
- BR112018007118A2 BR112018007118A2 BR112018007118A BR112018007118A BR112018007118A2 BR 112018007118 A2 BR112018007118 A2 BR 112018007118A2 BR 112018007118 A BR112018007118 A BR 112018007118A BR 112018007118 A BR112018007118 A BR 112018007118A BR 112018007118 A2 BR112018007118 A2 BR 112018007118A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- deficiency disorder
- reducing
- dopamine deficiency
- dopamine
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 14
- 229960003638 dopamine Drugs 0.000 title abstract 7
- 230000007812 deficiency Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 5
- 208000012661 Dyskinesia Diseases 0.000 title 3
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 238000011866 long-term treatment Methods 0.000 title 1
- 238000004806 packaging method and process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 101150106671 COMT gene Proteins 0.000 abstract 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 abstract 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000003943 catecholamines Chemical class 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a novas combinações de tratamento para distúrbios de deficiência de dopamina anormais, e condições relacionadas, compreendendo derivados de catecolamina deuterado e inibidores de catecol-o-metil-transferase (comt).The present invention relates to novel treatment combinations for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-o-methyl transferase (comt) inhibitors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562284800P | 2015-10-09 | 2015-10-09 | |
PCT/IB2016/056021 WO2017060870A1 (en) | 2015-10-09 | 2016-10-07 | Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018007118A2 true BR112018007118A2 (en) | 2018-12-11 |
Family
ID=57209653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018007118A BR112018007118A2 (en) | 2015-10-09 | 2016-10-07 | method for treating a dopamine deficiency disorder, method for improving active motor time without dyskinesia in a patient with parkinson's disease, method for reducing dyskinesia in an individual with a dopamine deficiency disorder, method for reducing inactive motor time in an individual with a dopamine deficiency disorder, method for reducing striatal dopamine level fluctuations in an individual with a dopamine deficiency disorder, method for reducing dyskinesia in an individual with a dopamine deficiency disorder after long-term treatment, pharmaceutical composition and packaging |
Country Status (8)
Country | Link |
---|---|
US (2) | US20170165381A1 (en) |
EP (1) | EP3359148A1 (en) |
JP (1) | JP2018530612A (en) |
AR (1) | AR106313A1 (en) |
BR (1) | BR112018007118A2 (en) |
MX (1) | MX2018004339A (en) |
TW (1) | TW201720443A (en) |
WO (1) | WO2017060870A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3111589C (en) | 2018-09-13 | 2023-12-19 | University Of Canberra | Methods of inhibition |
CN109293484B (en) * | 2018-10-22 | 2021-09-28 | 南京大学 | Method for preparing deuterated aldehyde from carboxylic acid under blue light irradiation by using iridium complex as catalyst |
GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830993A (en) | 1958-04-15 | Quinolizine derivatives | ||
US3045021A (en) | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
DE10261807A1 (en) | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterated catecholamine derivatives and medicinal products containing these compounds |
RS55142B1 (en) | 2006-02-17 | 2016-12-30 | Ratiopharm Gmbh | Deuterated catecholamine derivatives and medicaments comprising said compounds |
EP2604290A3 (en) | 2006-05-02 | 2013-07-10 | The Trustees of The University of Pennsylvania | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
EA018378B1 (en) | 2006-11-08 | 2013-07-30 | Ньюрокрайн Байосайенсиз, Инк. | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11b-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
AU2014214055A1 (en) * | 2013-02-05 | 2015-07-16 | Teva Pharmaceuticals International Gmbh | Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds |
-
2016
- 2016-10-07 BR BR112018007118A patent/BR112018007118A2/en not_active IP Right Cessation
- 2016-10-07 JP JP2018537734A patent/JP2018530612A/en active Pending
- 2016-10-07 EP EP16788231.5A patent/EP3359148A1/en not_active Withdrawn
- 2016-10-07 TW TW105132542A patent/TW201720443A/en unknown
- 2016-10-07 AR ARP160103097A patent/AR106313A1/en unknown
- 2016-10-07 MX MX2018004339A patent/MX2018004339A/en unknown
- 2016-10-07 WO PCT/IB2016/056021 patent/WO2017060870A1/en active Application Filing
-
2017
- 2017-01-09 US US15/401,270 patent/US20170165381A1/en not_active Abandoned
-
2019
- 2019-08-29 US US16/555,915 patent/US20200121812A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3359148A1 (en) | 2018-08-15 |
AR106313A1 (en) | 2018-01-03 |
WO2017060870A1 (en) | 2017-04-13 |
JP2018530612A (en) | 2018-10-18 |
MX2018004339A (en) | 2019-04-15 |
US20170165381A1 (en) | 2017-06-15 |
US20200121812A1 (en) | 2020-04-23 |
TW201720443A (en) | 2017-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121826T1 (en) | CARBINDOPA AND L-DOPA PRODRUGS AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | |
MX365206B (en) | Method for treatment of parkinson's disease. | |
MX2022007989A (en) | Compositions and methods for treating pterygium. | |
NI201600051A (en) | COMBINATIONS OF HISTONE DESACETILASE INHIBITORS AND IMMUNOMODULATING DRUGS | |
BR112016003201A2 (en) | selective grp94 inhibitors and uses thereof | |
BR112017009584A2 (en) | retinitis pigmentosa treatment with n-acetylcysteine amide | |
EP4299128A3 (en) | Dopa decarboxylase inhibitor compositions | |
MX2017002610A (en) | INHIBITORS OF A-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE. | |
MX2020001875A (en) | Polymorphic form of tg02. | |
BR112018007118A2 (en) | method for treating a dopamine deficiency disorder, method for improving active motor time without dyskinesia in a patient with parkinson's disease, method for reducing dyskinesia in an individual with a dopamine deficiency disorder, method for reducing inactive motor time in an individual with a dopamine deficiency disorder, method for reducing striatal dopamine level fluctuations in an individual with a dopamine deficiency disorder, method for reducing dyskinesia in an individual with a dopamine deficiency disorder after long-term treatment, pharmaceutical composition and packaging | |
BR112019005040A2 (en) | pridopidine application for rett syndrome treatment | |
BR112016028316A2 (en) | oral pharmaceutical composition of isotretinoin, its preparation process and treatment method | |
BR112017019971A2 (en) | antisense-induced exon exclusion in myostatin | |
MX2019004321A (en) | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase. | |
NI201800031A (en) | BRAIN PENETRATING CHROMONE OXIMA DERIVATIVES FOR LEVODOPA-INDUCED DYSKINESIA THERAPY | |
IL283654A (en) | Decarboxylase inhibitors for treating parkinson's disease | |
MX2020005336A (en) | Deuterated analogs of d-serine and uses thereof. | |
WO2016134257A8 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | |
BR112018007768A2 (en) | compositions and methods for treating homocystinuria | |
BR112017015613A2 (en) | levodopa and carbidopa intestinal gel and methods of use | |
BR112018005602A2 (en) | composition to treat pain | |
EA201792406A1 (en) | ANTI-SEMANTIC OLIGONUCLEOTIDE FOR THE TREATMENT OF DYSTROPHIC BULSE EPIDERMOLYSIS | |
WO2015188198A3 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
BR112016011999A2 (en) | AMIDE DERIVATIVES FOR GPR119 AGONIST | |
IN2013MU03428A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |